Stifel Financial Corp Global Blood Therapeutics, Inc. Transaction History

Stifel Financial Corp

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$22.3 - $37.39 $7,202 - $12,076	323 Added 5.28%	6,436 $205,000
Q1 2022 May 13, 2022	SELL	$25.68 - $35.59 $470,021 - $651,403	-18,303 Reduced 74.96%	6,113 $211,000
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $62,673 - $101,334	2,517 Added 11.49%	24,416 $715,000
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $355,751 - $521,341	13,962 Added 175.91%	21,899 $558,000
Q2 2021 Aug 13, 2021	SELL	$32.46 - $43.42 $21,131 - $28,266	-651 Reduced 7.58%	7,937 $278,000
Q1 2021 May 14, 2021	BUY	$38.94 - $50.85 $8,839 - $11,542	227 Added 2.71%	8,588 $350,000
Q4 2020 Feb 12, 2021	BUY	$37.65 - $63.77 $61,482 - $104,136	1,633 Added 24.27%	8,361 $362,000
Q3 2020 Nov 16, 2020	SELL	$52.76 - $74.49 $530,449 - $748,922	-10,054 Reduced 59.91%	6,728 $371,000
Q2 2020 Aug 14, 2020	BUY	$48.73 - $81.82 $71,438 - $119,948	1,466 Added 9.57%	16,782 $1.06 Million
Q1 2020 May 14, 2020	SELL	$41.72 - $87.2 $85,859 - $179,457	-2,058 Reduced 11.85%	15,316 $779,000
Q4 2019 Feb 13, 2020	BUY	$45.7 - $81.86 $192,214 - $344,303	4,206 Added 31.94%	17,374 $1.38 Million
Q3 2019 Nov 19, 2019	BUY	$45.35 - $57.91 $10,022 - $12,798	221 Added 1.71%	13,168 $629,000
Q3 2019 Nov 13, 2019	BUY	$45.35 - $57.91 $48,841 - $62,369	1,077 Added 9.07%	12,947 $619,000
Q2 2019 Aug 14, 2019	BUY	$52.6 - $63.29 $22,039 - $26,518	419 Added 3.66%	11,870 $618,000
Q1 2019 May 14, 2019	BUY	$39.99 - $53.48 $17,555 - $23,477	439 Added 3.99%	11,451 $599,000
Q4 2018 Feb 13, 2019	BUY	$31.54 - $46.67 $347,318 - $513,930	11,012 New	11,012 $439,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.